February 1, 2010Expert Review of Cardiovascular Therapy
Efficacy and safety of nesiritide in patients with acute decompensated heart failure
Key result
The impact of nesiritide on important clinical end points in acute decompensated heart failure, beyond symptomatic and hemodynamic improvement, remains unknown.
Why the study?
Does nesiritide improve clinical endpoints beyond symptomatic and hemodynamic improvement in patients with acute decompensated heart failure?
Population
Patients with acute decompensated heart failure
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Unknown effects of nesiritide on hard endpoints in acute decompensated HF may warrant clinical caution; leaves open need for dedicated outcome trials.
Structured PICO
Does nesiritide improve clinical endpoints beyond symptomatic and hemodynamic improvement in patients with acute decompensated heart failure?
P
Population
Patients with acute decompensated heart failure
I
Intervention
Nesiritide
The impact of nesiritide on important clinical endpoints beyond symptomatic and hemodynamic improvement in acute decompensated heart failure remains unknown.
Cite This Study
DeWald et al. (2010) conducted a review in Acute decompensated heart failure. Nesiritide was evaluated. The impact of nesiritide on important clinical end points in acute decompensated heart failure, beyond symptomatic and hemodynamic improvement, remains unknown.